As general counsel for the clinical-stage biopharma company, Alex Nemiroff is guided by his experiences as the father of a child with a rare and incurable disease When he was 36 years old, Alex ...
UTHealth Houston's SCN2A Multidisciplinary Center is led by, from left to right, Samden Lhatoo, MD; Gretchen Von Allmen, MD; and Dennis Lal, PhD. In recognition of its expertise in treating ...
Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen FDA agreed to proposed changes to the EMBRAVE3 trial design to be a single-arm, ...
Could CRISPR Fix this Severe Childhood Brain Disorder? A technology that activates healthy genes reduced seizures in a mouse model of a severe genetic neurological condition. When brain development ...
CAMBRIDGE, Mass. and SAN FRANCISCO, Sept. 17, 2025 /PRNewswire/ -- The laboratories of Dr. Kevin Bender and Dr. Nadav Ahituv at the University of California, San Francisco, today announced the ...
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines (PRAX), Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Detailed price information for Praxis Precision Medicines Inc (PRAX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback